Nanobiotix CEO: Curadigm Spin-Out Platform Could ‘Redefine’ Drug-Body Balance
Laurent Levy tells Scrip Nanobiotix’s freshly-created subsidiary Curadigm aims to improve bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.
You may also be interested in...
AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.
Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.
Novo Nordisk’s 6 August Q2 update will be scrutinized for clues on its plans for semaglutide in obesity, sales data for diabetes drugs Rybelsus and Ozempic, and likely M&A.